Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF), a Canadian developer of pharmaceutical-grade barium and iodine contrast media, announced it is evaluating three potential sites in the United States for its planned integrated manufacturing facility. The company is conducting a comprehensive analysis of candidate locations, focusing on proximity to iodine brine sources, which are expected to support over 70% of future revenue, as well as logistics, infrastructure, skilled labor access, and government incentive packages.
Strong candidate locations have been identified in Oklahoma and Texas due to their proximity to Voyageur’s iodine extraction initiatives in Oklahoma’s Anadarko Basin, robust transportation infrastructure including rail, highways, and port access, and a competitive business climate with low taxes and cost-effective land and energy. The company is actively engaging with economic development authorities and will select the site offering the most attractive overall combination of factors, with a strong emphasis on incentive support.
The planned facility will receive concentrated iodine liquor from Voyageur’s proprietary closed-loop Streamlined Iodine Process and high-purity barite from the Frances Creek project. Unlike conventional manufacturers that rely on imported iodine flakes or intermediates, this integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading and sterile injectable manufacturing. Management believes this will create the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents at materially lower cost, with enhanced sustainability and supply security for U.S. hospitals and government customers.
Key project highlights include cost leadership through vertical integration, significant opportunities for U.S. federal and state funding and incentives, creation of 150–250 direct high-skilled jobs, and substantial indirect employment through construction and suppliers. The facility is expected to generate significant annual economic activity and major local tax revenue. Voyageur plans to collaborate with post-secondary institutions to establish pharmaceutical training programs and talent pipelines.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: “This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. The jurisdiction that provides Voyageur with the most significant incentive package will secure this transformative project and its substantial long-term economic benefits.”
Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing and regulatory approvals. This announcement builds on Voyageur’s ongoing collaboration with Bayer and recent advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use. The company believes the project aligns with U.S. priorities for domestic critical minerals, pharmaceutical onshoring, and rural economic development.
For more information, visit Voyageur Pharmaceuticals.
